Gilead Sciences Inc(GILD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low135.91
Day High138.43
Open:136.81
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Gilead Sciences (GILD) Gets a Hold from Barclays
StockStory
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?
GILD
Motley Fool
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
StockStory
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
GILD
Motley Fool
Compugen (CGEN) Q2 2026 Earnings Call Transcript
StockStory
3 Healthcare Stocks with Open Questions
SHC
Zacks Investment Research
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
Tipranks
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Staar Surgical (STAA) and Elanco Animal Health (ELAN)
Tipranks
Analysts Offer Insights on Healthcare Companies: Niagen Bioscience (NAGE) and Gilead Sciences (GILD)
Tipranks
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)
Tipranks
Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU), Arrowhead Pharmaceuticals (ARWR) and Gilead Sciences (GILD)
Tipranks
Gilead Sciences (GILD) Gets a Buy from Wells Fargo
Tipranks
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Danaher (DHR) and Henry Schein (HSIC)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pediatrix Medical Group (MD), Certara (CERT) and Gilead Sciences (GILD)
StockStory
GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure
GILD
Tipranks
Gilead Sciences (GILD) Receives a Buy from Scotiabank
StockStory
Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026
GILD
Tipranks
Gilead’s GS-2426 Phase 1 Trial Targets MTAP-Deleted Tumors: What Investors Should Know
StockStory
Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For
GILD

Profile

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.